Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.37 and traded as high as $1.56. Cortexyme shares last traded at $1.54, with a volume of 48,558 shares trading hands.
Cortexyme Stock Performance
The firm has a market cap of $45.53 million, a PE ratio of -0.51 and a beta of 1.40. The stock has a 50 day simple moving average of $1.61 and a two-hundred day simple moving average of $1.38.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- What is the S&P 500 and How It is Distinct from Other Indexes
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- How to Capture the Benefits of Dividend Increases
- 3 Stocks to Buy While Others Stay on the Sidelines
- What is Put Option Volume?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
